Improving Medicine Use for Children: A Global Imperative

S M MacLeod1

  • 1Department of Pediatrics, University of British Columbia, British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.

Insights

Pediatric clinical pharmacology needs more skilled professionals to develop safe medicines for children. A global shortage of these experts, especially in low-income nations, hinders progress in child health.

Area of Science:

  • Pediatric pharmacology
  • Medicinal treatment development
  • Clinical pharmacy research

Background:

  • Optimal medical care for children necessitates a robust pipeline of validated medicinal treatments.
  • Current efforts are insufficient to meet the future demand for pediatric therapeutics.
  • A critical gap exists in the availability of skilled pediatric clinical pharmacologists and pharmacists.

Discussion:

  • The development of pediatric medicines requires specialized expertise in research and education.
  • A documented shortfall in human resources impacts the advancement of pediatric pharmacotherapy.
  • This deficit is particularly pronounced in low- and lower-middle-income countries.

Key Insights:

  • Expanding the workforce of pediatric clinical pharmacologists and pharmacists is essential.
  • Enhanced training in research and educational methodologies is crucial for these professionals.
  • Addressing the human resource gap is vital for improving child health outcomes globally.

Outlook:

  • Future pediatric drug development hinges on cultivating a skilled workforce.
  • Investment in specialized training programs is recommended.
  • International collaboration can help mitigate shortages in resource-limited settings.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
628
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
586
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304